SGO 2021 - Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer (Virtual Meeting)
Mar 19 - Mar 25, 2021 | SeattleWAUS
LARVOL is not affiliated with Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 81 abstracts linked to Trials
[VIRTUAL] ENPAC: Phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma
[VIRTUAL] Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
[VIRTUAL] A proof of concept randomized phase 2 non-inferiority trial on simple versus modified radical hysterectomy in IA2-IB1 cervical cancer ≤ 2cm (LESSER)
[VIRTUAL] Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062)
[VIRTUAL] Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase II KEYNOTE-158 study
[VIRTUAL] A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer
[VIRTUAL] Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
[VIRTUAL] Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: A secondary analysis of the CLAP trial
[VIRTUAL] Efficacy of niraparib by timing of surgery and residual disease: A post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
[VIRTUAL] Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: Explor
[VIRTUAL] Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): A multicenter, randomized, controlled, open-label, phase II trial
[VIRTUAL] Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer
[VIRTUAL] Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase III study
[VIRTUAL] Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy
[VIRTUAL] Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer